Literature DB >> 7060321

Active metabolites of imipramine and desipramine in man.

W Z Potter, H M Calil, T A Sutfin, A P Zavadil, W J Jusko, J Rapoport, F K Goodwin.   

Abstract

Active hydroxy metabolites of imipramine (IMI) and desipramine (DMI) have been quantified in plasma and cerebrospinal fluid (CSF) from patients at steady-state. In plasma of prepubescent boys and adults the concentration of unconjugated 2-hydroxyimipramine is only 15% to 25% that of IMI; 2-hydroxydesipramine (OH-DMI) concentration, however, is usually 50% that of DMI and in some cases OH-DMI is the predominant compound. In CSF from adult patients the ratio of concentrations of OH-DMI/DMI is higher than in plasma. Judging from the CSF/plasma ratio 12% of DMI exists in the free form at steady state, whereas 16% of OH-DMI is free (P less than 0.02). There is no evidence for saturation of hydroxylation within the therapeutic dose and concentration ranges investigated. On the basis of a steady-state OH-DMI/DMI ratio of less than 1/30 in plasma 5% of the population studied could be classified as deficient DMI hydroxylators. This in the same as the incidence of deficient debrisoquine hydroxylators reported in other populations.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7060321     DOI: 10.1038/clpt.1982.50

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  25 in total

1.  Relationship between plasma desipramine levels, CYP2D6 phenotype and clinical response to desipramine: a prospective study.

Authors:  E Spina; C Gitto; A Avenoso; G M Campo; A P Caputi; E Perucca
Journal:  Eur J Clin Pharmacol       Date:  1997       Impact factor: 2.953

2.  Tricyclic antidepressants block N-methyl-D-aspartate receptors: similarities to the action of zinc.

Authors:  I J Reynolds; R J Miller
Journal:  Br J Pharmacol       Date:  1988-09       Impact factor: 8.739

Review 3.  Formation of active metabolites of psychotropic drugs. An updated review of their significance.

Authors:  S Caccia; S Garattini
Journal:  Clin Pharmacokinet       Date:  1990-06       Impact factor: 6.447

4.  Comparison of the metabolism of the three antidepressants amitriptyline, imipramine, and chlorimipramine in vitro in rat liver microsomes.

Authors:  R Krüger; G Hölzl; H J Kuss; L Schefold
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

5.  The analysis and disposition of imipramine and its active metabolites in man.

Authors:  T A Sutfin; C L DeVane; W J Jusko
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

6.  Cerebral and blood pharmacokinetics of imipramine and its active metabolites in the pregnant rat.

Authors:  C L DeVane; J W Simpkins; S A Stout
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

Review 7.  The Role of Metabolites of Antidepressants in the Treatment of Depression.

Authors:  M V Rudorfer; W Z Potter
Journal:  CNS Drugs       Date:  1997-04       Impact factor: 5.749

8.  Desipramine pharmacokinetics in Chinese and Caucasian volunteers.

Authors:  M V Rudorfer; E A Lane; W H Chang; M D Zhang; W Z Potter
Journal:  Br J Clin Pharmacol       Date:  1984-04       Impact factor: 4.335

9.  Phase I metabolism of imipramine by microsomes of small intestine in comparison with metabolism by liver microsomes.

Authors:  W Christ; W Hecker; H Junge; G Stille
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1983-06       Impact factor: 3.000

Review 10.  Steady-state kinetics of doxepin and imipramine in Saudi patients with interethnic comparison.

Authors:  A el-Yazigi; K Chaleby
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.